pirfenidone
information and resources from the National Cancer Institute
NCI Thesaurus | pirfenidone
An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. NCI Thesaurus | pirfenidone
An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis.
|
|
|
|
news articles
InterMune to Present at the Bear Biotech West Coast Confab Mar 16, 2006
PR Newswire (press release), ...includes Actimmune(R) (interferon gamma-1b), which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF, and pirfenidone, which is ...
InterMune Divesting Infergen For $135.5M, Cuts Work Force Nov 29, 2005
BioWorld Online (subscription), ..."We could go out and raise a great sum of money that would be highly dilutive to shareholders, and/or partner pirfenidone [the Phase III compound for ...
InterMune Sharpens Focus on Key Development Programs and ... Nov 28, 2005
Yahoo! News (press release) ...its corporate strategy to direct resources on three key development programs -- Actimmune® for idiopathic pulmonary fibrosis (IPF), pirfenidone for IPF, and ...
InterMune Elects David S. Kabakoff, Ph.D. To Board Of Directors Dec 1, 2005
PR Newswire (press release), The pulmonology portfolio includes Actimmune(R) (interferon gamma-1b), pirfenidone and research programs. Actimmune(R) is being ...
|
|
